The risk of respiratory tract infections in patients with psoriasis treated with interleukin 23 pathway–inhibiting biologics: A meta-estimate of pivotal trials relevant to decision making during the COVID-19 pandemic - 10/10/20
Doi : 10.1016/j.jaad.2020.06.1014
Maha N. Syed, MBBS a, Daniel B. Shin, PhD a, Marilyn T. Wan, MBChB, MPH a, Kevin L. Winthrop, MD, MPH b, Joel M. Gelfand, MD, MSCE a, c, ⁎ 
a Department of Dermatology, University of Pennsylvania Perelman School of Medicine, Philadelphia, Pennsylvania
b Division of Infectious diseases and Public Health, Oregon Health and Sciences University, Portland, Oregon
c Department of Biostatistics, Epidemiology and Informatics, Perelman School of Medicine at the University of Pennsylvania, Philadelphia, Pennsylvania
∗Correspondence to: Joel M. Gelfand, MD, MSCE, Department of Dermatology, 3400 Civic Center Boulevard, Perelman Center for Advanced Medicine, South Tower, Office 730, Philadelphia, PA, 19104Department of Dermatology3400 Civic Center BoulevardPerelman Center for Advanced MedicineSouth TowerOffice 730PhiladelphiaPA19104
Bienvenue sur EM-consulte, la référence des professionnels de santé.
Article gratuit.
Connectez-vous pour en bénéficier!
| Funding sources: Supported in part by a grant (P30AR069589-03) from the National Institutes of Health (to Dr Gelfand). |
|
| Disclosure: Drs Syed and Wan are supported in part by a grant from Pfizer. Dr Winthrop receives grants from Bristol Myers Squibb and Pfizer and is a consultant for UCB, AbbVie, Lilly, Bristol Myers Squibb, Pfizer, GlaxoSmithKline, and Roche. Dr Gelfand served as a consultant for Bristol Myers Squibb, Boehringer Ingelheim, GlaxoSmithKline, Janssen Biologics, Novartis Corp, Regeneron, UCB (data safety and monitoring board), Sanofi, Pfizer Inc, receiving honoraria; receives research grants (to the Trustees of the University of Pennsylvania) from AbbVie, Janssen, Novartis Corp, Sanofi, Celgene, Ortho Dermatologics, and Pfizer Inc; has received payment for continuing medical education work related to psoriasis that was supported indirectly by Eli Lilly and Company and Ortho Dermatologics; is a copatent holder of resiquimod for the treatment of cutaneous T-cell lymphoma; and is a deputy editor for the Journal of Investigative Dermatology, receiving honoraria from the Society for Investigative Dermatology. Dr Shin has no conflicts of interest to declare. |
|
| IRB approval status: Not applicable. |
|
| Reprints not available from the author(s). |
© 2020
American Academy of Dermatology, Inc.. Publié par Elsevier Masson SAS. Tous droits réservés.
Vol 83 - N° 5
P. 1523-1526 - novembre 2020 Retour au numéro
Article précédent
- Heritability of tanning addiction: A twin concordance study
- Raghav Tripathi, Konrad D. Knusel, Rishabh S. Mazmudar, Harib H. Ezaldein, Jeremy S. Bordeaux, Jeffrey F. Scott
- Sensitivity of Fite-Faraco versus auramine-rhodamine in mycobacterial infection
- Alan N. Snyder, Heather O'Connor, John G. Plante, Latiffa J. Smith, Dirk M. Elston
Bienvenue sur EM-consulte, la référence des professionnels de santé.